Disease · MONDO_0003198

small intestine adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. small intestine adenocarcinoma. Diseases, record MONDO_0003198. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003198

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: small intestine adenocarcinoma; Open Targets
Open Targets ID: MONDO_0003198; Open Targets
Other names: adenocarcinoma - small intest., adenocarcinoma of small bowel, adenocarcinoma of small instestine, adenocarcinoma of small intestine, adenocarcinoma of the small bowel, adenocarcinoma of the small intestine, small bowel adenocarcinoma, small intestinal adenocarcinoma; Open Targets
Disease Ontology: DOID:4906; Disease Ontology
NCI Thesaurus: C7888; NCI Thesaurus
Orphanet: ORPHA:104075; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 23 drugs, from ClinicalTrials.gov; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	4	4	1	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AVELUMAB	CHEMBL3833373	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BINTRAFUSP ALFA	CHEMBL4298024	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP1	DNA topoisomerase 1	2	DNA topoisomerase I inhibitor	Phase 2	https://conductscience.org/library/genes/7150	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Phase 2	206	2023-08-21	Cancer	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT00001880	Stem Cell Transplantation for Metastatic Solid Tumors	Phase 2	42	2021-11-10	Neoplasm Metastasis	CYCLOSPORINE, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT02949219	Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery	Phase 2	41	2020-01-10	Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01730586	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Phase 2	34	2020-01-18	Colorectal Cancer, Cancer of Gastrointestinal Tract	PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00433550	Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer	Phase 2	33	2017-08-24	Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer	CAPECITABINE, IRINOTECAN HYDROCHLORIDE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT04491955	Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers	Phase 2	32	2023-11-14	Small Bowel Cancers, Colorectal Cancers	BINTRAFUSP ALFA, IMMUNOCYTOKINE NHS-IL12, NOGAPENDEKIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT00354887	Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater	Phase 2	31	2011-07-14	Gastrointestinal Cancer	CAPECITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01208103	Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma	Phase 2	30	2020-01-18	Ampulla of Vater Adenocarcinoma, Small Intestinal Adenocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Ampulla of Vater Cancer AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Ampulla of Vater Cancer AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8	BEVACIZUMAB, CAPECITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01202409	CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater	Phase 2	19	2020-02-21	Gastrointestinal Cancer	PANITUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03000179	Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma	Phase 2	8	2022-04-14	Adenocarcinoma	AVELUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39754977	RESULT	1	PubMed
19164203	RESULT	1	PubMed
41520164	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
37219859	DERIVED	1	PubMed
37059834	DERIVED	1	PubMed
36108341	DERIVED	1	PubMed
34838156	DERIVED	1	PubMed
32818466	DERIVED	1	PubMed
30590606	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003198

GET https://conductscience.org/api/diseases/v1/MONDO_0003198/drugs?page=2

API reference For AI assistants